China’s disruptive-tech push, US bio-war fears, Huawei’s chip ambition—plus nuclear test opacity: what’s next?

China’s People’s Liberation Army marked its 99th anniversary on August 1 and is now roughly one year from its centenary goals, with a reported focus on “disruptive” technologies and asymmetric warfare concepts. The SCMP piece frames the PLA’s modernization as a multi-year evolution that links past capabilities to present experimentation and future operational doctrine. The emphasis on disruptive technologies signals a deliberate attempt to compress decision cycles and complicate an adversary’s targeting and defense. While the article is part of a series, its thrust is clear: the PLA is treating emerging tech as a strategic lever rather than a supporting tool. In parallel, a PBS interview raises the question of whether the United States is prepared for biological warfare, centering on the idea that weaponized pathogens could be uniquely catastrophic and hard to attribute. The discussion with Annie Jacobsen—author of Biological War: A Scenario—highlights preparedness and response gaps as a core national-security concern, even if the segment is framed as scenario-based analysis rather than a confirmed incident. Together, the PLA’s “disruptive” technology narrative and the US bio-war preparedness debate point to a broader competition over unconventional capabilities and resilience. The power dynamic is asymmetric: China appears to be investing in technology-driven operational disruption, while the US is being pressed to harden public-health and security systems against low-visibility threats. On the technology front, another SCMP report spotlights Huawei chip-design strategy through the perspective of Liao Heng, describing a shift from skepticism about building world-class semiconductors to a more aggressive corporate and engineering mindset. This matters for markets because semiconductors are the enabling layer for advanced military systems, AI, sensors, and communications—precisely the domains associated with disruptive warfare. The US–China tech competition implied by Huawei’s internal strategy reinforces expectations of continued export controls, supply-chain fragmentation, and higher compliance costs for global chip ecosystems. Separately, a SWP-linked item on “China’s Secret Nuclear Tests” keeps attention on nuclear transparency and verification, which can influence risk premia for defense contractors, insurance, and strategic commodities tied to geopolitical uncertainty. What to watch next is whether these narratives translate into measurable policy and capability signals: PLA doctrine updates, procurement patterns for emerging tech, and any visible changes in training or exercises that reflect asymmetric disruption. On the US side, the key trigger is whether biological-threat preparedness moves from scenario discussion to concrete funding, procurement, and interagency coordination milestones, including lab capacity, surveillance, and countermeasure stockpiles. For semiconductors, watch for Huawei’s progress markers (design milestones, manufacturing workarounds, and ecosystem partnerships) alongside any tightening or easing of US export restrictions. Finally, for nuclear risk, monitor verification and transparency initiatives, third-party assessments, and any diplomatic signaling that could either reduce uncertainty or harden worst-case planning. The near-term escalation risk is driven less by confirmed attacks and more by accelerating capability narratives and preparedness postures.

Geopolitical Implications

• 01

  Unconventional capability competition is expanding beyond conventional force posture into biosecurity, verification, and technology-enabled disruption.

• 02

  Asymmetric warfare doctrine and resilience planning can drive faster procurement cycles and tighter export-control regimes, affecting global tech supply chains.

• 03

  Nuclear transparency disputes can harden deterrence postures and increase the risk of miscalculation even without new kinetic incidents.

Key Signals

• —PLA procurement and training signals that explicitly map to disruptive tech and asymmetric operations.
• —US biodefense milestones: lab capacity expansion, surveillance upgrades, countermeasure stockpile decisions, and interagency exercises.
• —Huawei semiconductor progress markers and any changes in workaround strategies under export-control pressure.
• —Diplomatic or technical verification steps related to nuclear testing transparency, including third-party assessments.